Skip to main content

Moderna sues Pfizer and BioNTech for patent infringement involving COVID-19 vaccines

Moderna sued Pfizer and BioNTech “for infringing patents central to (its) mRNA technology platform,” the company said in a news release Friday.

“Moderna believes that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna’s foundational mRNA technology. This groundbreaking technology was critical to the development of Moderna’s own mRNA COVID-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty,” the news release said.

Moderna said it believes Pfizer copied two key features of its patented technologies that is says are “critical to the success of mRNA vaccines.”

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,” said Moderna Chief Executive Officer Stéphane Bancel.

“This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck. As we work to combat health challenges moving forward, Moderna is using our mRNA technology platform to develop medicines that could treat and prevent infectious diseases like influenza and HIV, as well as autoimmune and cardiovascular diseases and rare forms of cancer.”

Both companies made tens of billions of dollars selling their coronavirus vaccines.

How to prepare for the resumption of federal student loan payments

For more than three years, borrowers had relief from federal student loan payments, but the pandemic-related pause is ending in October. The Department of Education says you'll get your first bill in September or October, and you'll have 21 days to make your first payment.
Read Next Story